Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study.

Karagianis J, Grossman L, Landry J, Reed VA, de Haan L, Maguire GA, Hoffmann VP, Milev R.

Schizophr Res. 2009 Aug;113(1):41-8. doi: 10.1016/j.schres.2009.05.024. Epub 2009 Jun 16. Erratum in: Schizophr Res. 2011 Dec;133(1-3):266.

PMID:
19535229
2.

An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study.

Karagianis J, Landry J, Hoffmann VP, Grossman L, de Haan L, Maguire G, Milev R, Holt S.

Int J Clin Pract. 2010 Oct;64(11):1520-9. doi: 10.1111/j.1742-1241.2010.02485.x.

PMID:
20846199
3.

Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.

Arranz B, San L, Dueñas RM, Centeno M, Ramirez N, Salavert J, Del Moral E.

Hum Psychopharmacol. 2007 Jan;22(1):11-5.

PMID:
17191265
5.
6.

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

Kinon BJ, Basson BR, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Feb;62(2):92-100.

PMID:
11247108
7.

A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.

Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD.

J Clin Psychiatry. 2008 Jul;69(7):1046-56.

PMID:
18605811
8.

Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets.

Crocq MA, Guillon MS, Bailey PE, Provost D.

Eur Psychiatry. 2007 Oct;22(7):453-4. Epub 2007 Aug 30.

PMID:
17761403
9.

A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population.

Rado J, von Ammon Cavanaugh S.

J Clin Psychopharmacol. 2016 Apr;36(2):163-8. doi: 10.1097/JCP.0000000000000469.

PMID:
26872112
10.

Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia.

Daly EJ, Kent JM, Janssens L, Newcomer JW, Hüsken G, De Boer P, Tritsmans L, Schmidt ME.

Ann Clin Psychiatry. 2013 Aug;25(3):173-83.

PMID:
23926573
11.

Weight loss during therapy with olanzapine orally disintegrating tablets: two case reports.

Kozumplik O, Uzun S, Jakovljević M.

Psychiatr Danub. 2009 Mar;21(1):72-4.

12.

Effect of olanzapine orally disintegrating tablet versus oral standard tablet on body weight in patients with schizophrenia: a randomized open-label trial.

Kusumi I, Honda M, Uemura K, Sugawara Y, Kohsaka M, Tochigi A, Koyama T.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Mar 30;36(2):313-7. doi: 10.1016/j.pnpbp.2011.11.004. Epub 2011 Nov 15.

PMID:
22119746
14.

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.

Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH.

Am J Psychiatry. 2008 Mar;165(3):352-8. doi: 10.1176/appi.ajp.2007.07010079. Epub 2008 Feb 1.

PMID:
18245179
15.

Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.

Kemp DE, Zhao J, Cazorla P, Landbloom RP, Mackle M, Snow-Adami L, Szegedi A.

J Clin Psychiatry. 2014 Mar;75(3):238-45. doi: 10.4088/JCP.12m08271.

PMID:
24499969
17.

Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.

Kwon JS, Choi JS, Bahk WM, Yoon Kim C, Hyung Kim C, Chul Shin Y, Park BJ, Geun Oh C.

J Clin Psychiatry. 2006 Apr;67(4):547-53.

PMID:
16669719
18.

Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.

Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW.

Clin Schizophr Relat Psychoses. 2011 Apr;5(1):17-25. doi: 10.3371/CSRP.5.1.3.

PMID:
21459735
19.

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC.

Am J Psychiatry. 2005 May;162(5):954-62.

PMID:
15863798
20.

Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.

Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, Adams DH, Lindenmayer JP, McEvoy JP, Buckley PF, Lieberman JA, Meltzer HY, Wilson DR, Citrome L.

J Clin Psychopharmacol. 2008 Aug;28(4):392-400. doi: 10.1097/JCP.0b013e31817e63a5.

PMID:
18626265

Supplemental Content

Support Center